Relmada Therapeutics Gross Profit 2011-2025 | RLMD

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Relmada Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	-	-	-	1.09 K	2.14 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.14 K	1.09 K	1.62 K

Quarterly Gross Profit Relmada Therapeutics

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	164	-	312	3.4 K	299	1.62 K	108	1.52 K	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.4 K	-3	928

Gross Profit of other stocks in the Drug manufacturers industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	69.9 M	-	-	$ 142 M	USA
Assertio Holdings ASRT	86.4 M	$ 0.73	-3.6 %	$ 51.9 M	USA
Aerie Pharmaceuticals AERI	57.8 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	79.5 M	$ 1.7	-2.59 %	$ 183 M	Canada
AcelRx Pharmaceuticals ACRX	-616 K	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	-1.43 M	-	0.86 %	$ 117 M	USA
Cronos Group CRON	-25.8 M	$ 3.07	-6.25 %	$ 1.6 B	Canada
Agile Therapeutics AGRX	10.6 M	-	10.11 %	$ 58.2 M	USA
Aurora Cannabis ACB	188 M	$ 5.11	-5.46 %	$ 86.3 M	Canada
Catalent CTLT	953 M	-	-	$ 11.5 B	USA
HEXO Corp. HEXO	-75.7 M	-	2.45 %	$ 38.1 M	Canada
DURECT Corporation DRRX	25.4 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	135 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	1.35 B	-	-	$ 28.9 M	Irlanda
Emergent BioSolutions EBS	318 M	$ 12.37	8.32 %	$ 633 M	USA
Evoke Pharma EVOK	-63.7 K	$ 10.96	0.09 %	$ 36.6 M	USA
Athenex ATNX	26.7 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	154 M	$ 21.43	0.3 %	$ 2.04 B	France
Evolus EOLS	182 M	$ 7.18	1.99 %	$ 445 M	USA
Harrow Health HROW	90.6 M	$ 46.29	-1.64 %	$ 1.51 B	USA
China Pharma Holdings CPHI	-1.99 M	$ 1.53	-1.92 %	$ 26.7 M	China
Bausch Health Companies BHC	6.25 B	$ 6.9	-0.36 %	$ 2.52 B	Canada
Organogenesis Holdings ORGO	366 M	$ 4.78	-0.83 %	$ 629 M	USA
Lannett Company LCI	33.2 M	-	1.15 %	$ 7.11 M	USA
Pacira BioSciences PCRX	314 M	$ 26.61	1.22 %	$ 1.23 B	USA
OrganiGram Holdings OGI	47.5 M	$ 1.8	-6.19 %	$ 402 M	Canada
Cumberland Pharmaceuticals CPIX	28.8 M	$ 3.11	22.92 %	$ 43.7 M	USA
Rockwell Medical RMTI	8.7 M	$ 0.88	-5.3 %	$ 20.5 M	USA
Sonoma Pharmaceuticals SNOA	5.46 M	$ 3.55	-1.11 %	$ 4.41 M	USA
PetIQ PETQ	253 M	-	1.64 %	$ 400 M	USA
Jupiter Wellness JUPW	-2.45 M	-	-	$ 33.6 M	USA
Perrigo Company plc PRGO	1.54 B	$ 12.77	-2.78 %	$ 1.75 B	USA
ProPhase Labs PRPH	70.7 M	$ 0.11	-0.35 %	$ 1.74 M	USA
Radius Health RDUS	221 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	48.2 M	-	-4.76 %	$ 65.3 M	USA
Sundial Growers SNDL	240 M	$ 1.99	-9.95 %	$ 3.37 M	Canada
Veru VERU	5.85 M	$ 2.4	-0.83 %	$ 324 M	USA
OptiNose OPTN	41.6 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	3.4 M	-	-27.8 %	$ 2.56 M	USA
cbdMD YCBD	12 M	$ 1.19	-0.83 %	$ 5.13 M	USA
SCYNEXIS SCYX	3.58 M	$ 0.64	-0.91 %	$ 30.6 M	USA
Tilray TLRY	147 M	$ 11.01	-9.4 %	$ 6.8 B	Canada
TherapeuticsMD TXMD	1.3 M	$ 1.7	-2.86 %	$ 17.7 M	USA
Zomedica Corp. ZOM	17.3 M	-	-0.21 %	$ 98 M	USA
Viatris VTRS	6.5 B	$ 11.68	0.29 %	$ 14.2 B	USA